* sars cov 2 infection confirmed cases, suspected cases or asymptomatic infection * sars cov 2 nucleic acid test positive * have a history of sars , mers infection (self report, on site inquiry * fever (axillary temperature \> 37.0 ℃), dry cough, fatigue, nasal obstruction, runny nose, pharyngeal pain, myalgia, diarrhea, shortness of breath and dyspnea occurred within 14 days before vaccination * axillary body temperature \> 37.0 ℃ before vaccination * previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated sars cov 2 vaccine have occurred. * have a history of convulsion, epilepsy, encephalopathy or mental illness or family history * congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc. * severe liver and kidney diseases, uncontrollable hypertension (systolic blood pressure ≥ 140 mmhg, diastolic blood pressure ≥ 90 mmhg), diabetic complications, malignant tumors, various acute diseases or acute attack period of chronic diseases * has been diagnosed with congenital or acquired immune deficiency, hiv infection, lymphoma, leukemia or other autoimmune diseases * diseases known or suspected include severe respiratory diseases, severe cardiovascular diseases, liver and kidney diseases, and malignant tumors. - hist ory of coagulation dysfunction (e.g. coagulation factor deficiency, coagulation disease) * receiving anti tb therapy * patients receiving immunotherapy or inhibitor therapy within 3 months (continuous oral or infusion for more than 14 * live attenuated va ccine is inoculated within 1 month before this vaccination , other vaccines are inoculated within 14 days before this vaccination * received blood products within 3 months before this vaccination * received other research drugs within 6 months before this vacc ination * investigator judged other circumstances that are not suitable for this clinical trial.

* sars cov 2 infection confirmed cases, suspected cases or asymptomatic infection * sars cov 2 nucleic acid test positive * have a history of sars , mers infection (self report, on site inquiry * fever (axillary temperature \> 37.0 ℃), dry cough, fatigue, nasal obstruction, runny nose, pharyngeal pain, myalgia, diarrhea, shortness of breath and dyspnea occurred within 14 days before vaccination * axillary body temperature \> 37.0 ℃ before vaccination * previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated sars cov 2 vaccine have occurred. * have a history of convulsion, epilepsy, encephalopathy or mental illness or family history * congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc. * severe liver and kidney diseases, uncontrollable hypertension (systolic blood pressure ≥ 140 mmhg, diastolic blood pressure ≥ 90 mmhg), diabetic complications, malignant tumors, various acute diseases or acute attack period of chronic diseases * has been diagnosed with congenital or acquired immune deficiency, hiv infection, lymphoma, leukemia or other autoimmune diseases * diseases known or suspected include severe respiratory diseases, severe cardiovascular diseases, liver and kidney diseases, and malignant tumors. - hist ory of coagulation dysfunction (e.g. coagulation factor deficiency, coagulation disease) * receiving anti tb therapy * patients receiving immunotherapy or inhibitor therapy within 3 months (continuous oral or infusion for more than 14 * live attenuated va ccine is inoculated within 1 month before this vaccination , other vaccines are inoculated within 14 days before this vaccination * received blood products within 3 months before this vaccination * received other research drugs within 6 months before this vacc ination * investigator judged other circumstances that are not suitable for this clinical trial.

- sars cov 2 infection confirmed cases, suspected cases or asymptomatic infection - sars cov 2 nucleic acid test positive - have a history of sars , mers infection (self report, on site inquiry - fever (axillary temperature > 37.0 ℃), dry cough, fatigue, nasal obstruction, runny nose, pharyngeal pain, myalgia, diarrhea, shortness of breath and dyspnea occurred within 14 days before vaccination - axillary body temperature > 37.0 ℃ before vaccination - previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated sars cov 2 vaccine have occurred. - have a history of convulsion, epilepsy, encephalopathy or mental illness or family history - congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc. - severe liver and kidney diseases, uncontrollable hypertension (systolic blood pressure ≥ 140 mmhg, diastolic blood pressure ≥ 90 mmhg), diabetic complications, malignant tumors, various acute diseases or acute attack period of chronic diseases - has been diagnosed with congenital or acquired immune deficiency, hiv infection, lymphoma, leukemia or other autoimmune diseases - diseases known or suspected include severe respiratory diseases, severe cardiovascular diseases, liver and kidney diseases, and malignant tumors. - hist ory of coagulation dysfunction (e.g. coagulation factor deficiency, coagulation disease) - receiving anti tb therapy - patients receiving immunotherapy or inhibitor therapy within 3 months (continuous oral or infusion for more than 14 - live attenuated va ccine is inoculated within 1 month before this vaccination , other vaccines are inoculated within 14 days before this vaccination - received blood products within 3 months before this vaccination - received other research drugs within 6 months before this vacc ination - investigator judged other circumstances that are not suitable for this clinical trial.

- sars cov 2 infection confirmed cases, suspected cases or asymptomatic infection - sars cov 2 nucleic acid test positive - have a history of sars , mers infection (self report, on site inquiry - fever (axillary temperature > 37.0 ℃), dry cough, fatigue, nasal obstruction, runny nose, pharyngeal pain, myalgia, diarrhea, shortness of breath and dyspnea occurred within 14 days before vaccination - axillary body temperature > 37.0 ℃ before vaccination - previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated sars cov 2 vaccine have occurred. - have a history of convulsion, epilepsy, encephalopathy or mental illness or family history - congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc. - severe liver and kidney diseases, uncontrollable hypertension (systolic blood pressure ≥ 140 mmhg, diastolic blood pressure ≥ 90 mmhg), diabetic complications, malignant tumors, various acute diseases or acute attack period of chronic diseases - has been diagnosed with congenital or acquired immune deficiency, hiv infection, lymphoma, leukemia or other autoimmune diseases - diseases known or suspected include severe respiratory diseases, severe cardiovascular diseases, liver and kidney diseases, and malignant tumors. - hist ory of coagulation dysfunction (e.g. coagulation factor deficiency, coagulation disease) - receiving anti tb therapy - patients receiving immunotherapy or inhibitor therapy within 3 months (continuous oral or infusion for more than 14 - live attenuated va ccine is inoculated within 1 month before this vaccination , other vaccines are inoculated within 14 days before this vaccination - received blood products within 3 months before this vaccination - received other research drugs within 6 months before this vacc ination - investigator judged other circumstances that are not suitable for this clinical trial.